Cargando…

Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study

In a clinical trial involving Japanese patients with osteoporosis, post hoc analyses were performed to evaluate the incidence of acute phase reactions (APRs) after infusion of zoledronic acid (ZOL). The results highlighted differences in baseline factors between patients with vs without APRs. Change...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiraki, Masataka, Kuroda, Tatsuhiko, Takeuchi, Yasuhiro, Sugimoto, Toshitsugu, Tanaka, Satoshi, Suzuki, Hiroaki, Hiraishi, Kazuki, Nakamura, Toshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531063/ https://www.ncbi.nlm.nih.gov/pubmed/34247263 http://dx.doi.org/10.1007/s00223-021-00884-7

Ejemplares similares

Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study
por: Kuroda, Tatsuhiko, et al.
Publicado: (2021)

Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide
por: Takeuchi, Yasuhiro, et al.
Publicado: (2015)

New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide
por: Tanaka, Sakae, et al.
Publicado: (2014)

Zoledronic acid infusion for prevention and treatment of osteoporosis
por: Sunyecz, John A
Publicado: (2010)

Characteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis
por: Ferreira, Bruno S. A., et al.
Publicado: (2021)

Six monthly intravenous zoledronic acid in childhood osteoporosis
por: Munns, CF, et al.
Publicado: (2013)

Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary
por: Orimo, Hajime, et al.
Publicado: (2012)

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
por: Nakamura, T., et al.
Publicado: (2016)

Prediction of Fracture Risk From Early‐Stage Bone Markers in Patients With Osteoporosis Treated With Once‐Yearly Administered Zoledronic Acid
por: Kasai, Hidefumi, et al.
Publicado: (2020)

Treatment of Transient Osteoporosis of the Hip with Intravenous Zoledronate - A Case Report -
por: Seok, Hyun, et al.
Publicado: (2011)

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
por: Lewiecki, E Michael
Publicado: (2010)

Acute effect of zoledronic acid infusion on atrial fibrillation development in patients with osteoporosis
por: İlgezdi, Zeynep Demet, et al.
Publicado: (2015)

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
por: Sugimoto, Toshitsugu, et al.
Publicado: (2017)

Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis
por: Gazoni, Fernanda Martins, et al.
Publicado: (2023)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate
por: Al-Bogami, Mohammed M., et al.
Publicado: (2015)

Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
por: Shigematsu, Takashi, et al.
Publicado: (2017)

Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial‐05 (JOINT‐05)
por: Tanaka, Shiro, et al.
Publicado: (2022)

Predicting the individualized risk of nonadherence to zoledronic acid among osteoporosis patients receiving the first infusion of zoledronic acid: development and validation of new predictive nomograms
por: Li, Chong, et al.
Publicado: (2022)

Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan
por: Inoue, Daisuke, et al.
Publicado: (2015)

Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosis
por: Jiang, Yan, et al.
Publicado: (2015)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

Intravenous Zoledronate 4 mg for the treatment of post-menopausal osteoporosis: A prospective open-labeled study
por: Arunthanachaikul, Thunyawarin, et al.
Publicado: (2021)

Acute uveitis following zoledronic acid infusion
por: Rathnam, Krishna Kumar, et al.
Publicado: (2009)

Three years of treatment with minodronate in patients with postmenopausal osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2011)

Role of zoledronic acid in the prevention and treatment of osteoporosis
por: Räkel, Agnès, et al.
Publicado: (2011)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2012)

Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer
por: Jun, Jong Hwa
Publicado: (2017)

Investigation of Intravenous Zoledronic Acid Therapy on Circulating Lymphocyte Subpopulation in Patients with Primary Osteoporosis: A Pilot Study
por: Cui, Min, et al.
Publicado: (2021)

Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
por: Yoon, Ji-Hee, et al.
Publicado: (2021)

Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia
por: Tripathy, Sujit Kumar, et al.
Publicado: (2020)

RTOG 0518: Randomized Phase III Trial to Evaluate Zoledronic Acid for Prevention of Osteoporosis and Associated Fractures in Prostate Cancer Patients
por: Kachnic, Lisa A., et al.
Publicado: (2013)

Intravenous Zoledronate for a Patient with Paget's Disease
por: Kim, Ki-Choul
Publicado: (2014)

Management of osteoporosis in the aging male: Focus on zoledronic acid
por: Piper, Paul K, et al.
Publicado: (2009)

Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis
por: Kong, Li, et al.
Publicado: (2020)

How zoledronic acid improves osteoporosis by acting on osteoclasts
por: Wang, Biao, et al.
Publicado: (2022)

THU442 A Case Of Early Medication Related Osteonecrosis Of The Jaw In Patient Receiving Intravenous Zoledronate For Treatment Of Osteoporosis
por: Ekpe, Victor, et al.
Publicado: (2023)

Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
por: Nakamura, Toshitaka, et al.
Publicado: (2014)

Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study
por: Holmes, Jarrod P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e5t6f6de10egbdfa1bpkja5o6s